Generic placeholder image

Current Drug Safety


ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Research Article

Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use

Author(s): Henrik V.B. Laursen*, Johan B. Røikjer, Jakob Dal and Morten Hasselstrøm Jensen

Volume 16, Issue 1, 2021

Published on: 19 August, 2020

Page: [73 - 81] Pages: 9

DOI: 10.2174/1574886315666200819114629

Price: $65


Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been associated with increased risk of diabetic ketoacidosis (DKA) in both people with type 1 and type 2 diabetes mellitus. Few studies using data from high-quality registries exist that attempt to determine the real- world impact of the increasing use of this drug.

Objective: The aim of this study was to investigate the incidence and risk of DKA in connection with SGLT2i treatment in Denmark between 2013-2017.

Methods: A nationwide retrospective cohort of people with type 2 diabetes mellitus using SGLT2i or glucagon-like peptide-1 receptor agonists (GLP1-RA) was established and analysed using both Cox-proportional hazard regression and Kaplan-Meier survival analysis.

Results: The 37,058 individuals included in the cohort, were made up of SGLT2i (10,923), GLP1- RA (18,849), SGLT2i+insulin (2,069), and GLP1-RA+insulin (10,178) users. The incidence rate (IR) of DKA was 0.84 (95% CI 0.49-1.44) and 0.53 (95% CI 0.36-0.77) for the SGLT2i and GLP1-RA groups, respectively. There was no statistically significant increase in the risk for DKA with SGLT2i use (HR 1.02, 95% CI, 0.44-2.36). However, for the SGLT2i+insulin and GLP1- RA+insulin groups, IRs were 3.47 (95% CI 1.92-6.27) and 0.97 (95% CI 0.68-1.37) respectively, and the risk was statistically significantly higher (HR 5.42, 95% CI 2.16-13.56).

Conclusion: We observed no significant increase in the risk of DKA for SGLT2i users compared to GLP1-RA. However, a significantly higher IR of DKA was observed with concomitant insulin use, and the risk of DKA was considerably higher for the SGLT2 group using insulin.

Keywords: Sodium-glucose cotransporter 2 inhibitors, retrospective cohort, diabetic ketoacidosis, hyperglycaemia, insulin, Kaplan- Meier.

Graphical Abstract
Henriksen OM, Prahl JB, Røder ME, Svendsen OL. Treatment of diabetic ketoacidosis in adults in Denmark: A national survey. Diabetes Res Clin Pract 2007; 77(1): 113-9.
[] [PMID: 17126447]
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166): 31-9.
[] [PMID: 30424892]
Lee PC, Ganguly S, Goh S-Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev 2018; 19(12): 1630-41.
[] [PMID: 30253050]
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf 2019; 18(4): 295-311.
[] [PMID: 30933547]
European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes 2018.
Wiviott SD, Raz I, Bonaca MP, et al. Declare–TIMI 58 investigators. dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347-57.
[] [PMID: 30415602]
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG outcome investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[] [PMID: 26378978]
Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644-57.
[] [PMID: 28605608]
Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study. BMJ 2018; 363: k4365.
[] [PMID: 30429124]
Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 2019; 104(8): 3077-87.
[] [PMID: 30835263]
Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7)(Suppl.): 38-41.
[] [PMID: 21775349]
Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(7)(Suppl.): 30-3.
[] [PMID: 21775347]
Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39(7)(Suppl.): 26-9.
[] [PMID: 21775346]
Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29(8): 541-9.
[] [PMID: 24965263]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461-98.
[] [PMID: 30288571]
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38(9): 1638-42.
[] [PMID: 26294774]
Jensen ML, Persson F, Andersen GS, et al. Incidence of ketoacidosis in the danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors-A nationwide, retrospective cohort study, 1995-2014. Diabetes Care 2017; 40(5): e57-8.
[] [PMID: 28283564]
Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System. Diabetologia 2017; 60(8): 1385-9.
[] [PMID: 28500396]
Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev 2017; 33(8)e2924
[] [PMID: 28736981]
Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017; 376(23): 2300-2.
[] [PMID: 28591538]
Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38(9): 1680-6.
[] [PMID: 26203064]
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38(9): 1687-93.
[] [PMID: 26078479]
Waylen AL, Riedel B. Sodium-glucose co-transporter 2 inhibitors in the peri-operative period: A warning to all clinicians. BJU Int 2019; 123(Suppl. 5): 6-7.
[] [PMID: 31116003]
Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: A systematic review. Diabet Med 2015; 32(6): 725-37.
[] [PMID: 25440507]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy